Cryoport (CYRX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $56.7 million, up 0.9% year-over-year, driven by 9% growth in Life Sciences Services and offset by a 13.7% decline in Life Sciences Products revenue.

• Supported a record 691 global clinical trials (79 in Phase III) and 17 commercial cell & gene therapies as of September 30, 2024.

• Services accounted for 69% of total Q3 2024 revenue, up from 64% in Q3 2023.

• Cost reduction and capital realignment strategies are underway, improving gross margin, adjusted EBITDA, and cash flow.

• Full-year 2024 revenue guidance of $225M–$235M was reaffirmed, with positive adjusted EBITDA targeted for 2025.

Financial highlights

• Q3 2024 total revenue was $56.7 million (+1% year-over-year); Life Sciences Services revenue was $39.3 million (+9%), while Life Sciences Products revenue was $17.4 million (–13.7%).

• Gross margin for Q3 2024 improved to 44.8% (Life Sciences Services: 46.0%, Products: 42.1%).

• Adjusted EBITDA for Q3 2024 was negative $2.4 million, an improvement from negative $3.1 million in Q3 2023.

• Net income for Q3 2024 was $0.8 million, compared to a net loss of $13.3 million in Q3 2023, mainly due to a $17.3 million gain on extinguishment of debt.

• Cash, cash equivalents, and short-term investments totaled $272.7 million as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $225M–$235M, with Q4 expected to see a step up in revenue.

• Cost reduction and capital realignment strategies are expected to drive a return to positive adjusted EBITDA in 2025.

• Expects continued growth in services but ongoing softness in product sales; more detailed 2025 guidance to be provided with Q4 results.

• Current liquidity and projected cash flows are expected to satisfy operational and capital requirements for at least the next twelve months.

• Macro and sector-specific challenges expected to persist in the near term.